Literature DB >> 19175874

Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.

M Friedrich-Rust1, J Theobald, S Zeuzem, J Bojunga.   

Abstract

SUMMARY: Thyroid disease is a common side-effect of interferon-based antiviral therapy for chronic hepatitis C, which may lead to dose reduction or discontinuation of therapy. The aim of this study was to investigate changes in ultrasound morphology, thyroid function, autoimmunity as well as predictive factors for the development of thyroid dysfunction in patients with hepatitis C virus infection treated with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin. A total of 59 patients with chronic hepatitis C assigned for antiviral treatment with PEG-IFN-alpha and ribavirin were enrolled into the study. All patients were subjected to an ultrasound examination of the thyroid gland before treatment, and after 1, 3 and 6 months of antiviral therapy. In addition, thyroid function and autoimmune status were determined at fixed time-points. Prior and during the course of therapy, 11 patients (19%) developed thyroid dysfunction (one hypothyroidism, nine hyperthyroidism, one hyperthyroidism followed by hypothyroidism). Hyperthyroidism was shown to be Graves' disease in one patient and destructive thyroiditis in nine patients. Power-Doppler ultrasound could differentiate between destructive thyroiditis and Graves' disease. A reduction in echogenicity suggestive for a destructive process of the thyroid gland was observed even before changes in thyroid function of antibody status could be measured. Risk factors for the development of thyroid dysfunction were age, female gender, pre-treatment thyroid volume, pre-existing thyroglobulin/thyroid peroxidase antibodies and viral load. Changes in thyroid function are a common side-effect occurring during antiviral therapy with PEG-IFN-alpha and ribavirin. Ultrasound presents a simple complementary tool for screening and follow-up during antiviral therapy, which helps to differentiate between the common types of hyperthyroidism and gives insight into morphological changes of the thyroid gland during antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19175874     DOI: 10.1111/j.1365-2893.2008.01059.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  8 in total

1.  A case of chronic hepatitis C patient of myocardial ischemia accompanied with interstitial pneumonia induced by pegylated interferon alpha-2a.

Authors:  Caihong Qu; Zhenda Zheng; Weimin Liu; Ju Jiao; Jieming Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

2.  Association of interferon-alpha and ribavirin-induced thyroid dysfunction with severity of disease and response to treatment in pakistani asian patients of chronic hepatitis C.

Authors:  Amina Nadeem; Muhammad Aslam
Journal:  Hepat Res Treat       Date:  2012-09-02

3.  Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C.

Authors:  Amina Nadeem; Muhammad Mazhar Hussain; Muhammad Aslam; Tassawar Hussain
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

Review 4.  Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Ugo Politti; Dilia Giuggioli; Clodoveo Ferri; Alessandro Antonelli
Journal:  Int J Endocrinol       Date:  2014-10-13       Impact factor: 3.257

5.  A systematic review and meta-analysis of endocrine-related adverse events associated with interferon.

Authors:  Linghuan Wang; Binqi Li; He Zhao; Peixin Wu; Qingzhen Wu; Kang Chen; Yiming Mu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

6.  Thyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors.

Authors:  Zehui Yan; Ke Fan; Yi Fan; Xiaohong Wang; Qing Mao; Guohong Deng; Yuming Wang
Journal:  Hepat Mon       Date:  2012-09-30       Impact factor: 0.660

Review 7.  Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis.

Authors:  Chandrasekharan Nair Kesavachandran; Frank Haamann; Albert Nienhaus
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

8.  Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients.

Authors:  Xiao-Rong Mao; Li-Ting Zhang; Hong Chen; Ping Xiao; You-Cheng Zhang
Journal:  Exp Ther Med       Date:  2014-05-14       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.